Press Releases

“This editorial explores its impact on expanding datasets, improving image quality, and enabling predictive oncology.”

BUFFALO, NY- September 6, 2024 – A new editorial was published in Oncotarget's Volume 15 on September 4, 2024, entitled, “Generative AI in oncological imaging: Revolutionizing cancer detection and diagnosis.”

Generative AI is revolutionizing oncological imaging, enhancing cancer detection and diagnosis. This editorial explores its impact on expanding datasets, improving image... continue reading >>

“In this research perspective, we discuss recent work from our lab describing an active role of HSPCs in AML and the potential implications.”

BUFFALO, NY- September 5, 2024 – A new research perspective was published in Oncotarget's Volume 15 on September 4, 2024, entitled, “Trained and ready - the case for an inflammatory memory for hematopoietic stem and progenitor cells in the AML niche.”

As noted in the abstract of this paper, lifelong hematopoiesis is sustained by the crosstalk between... continue reading >>

“As there is controversy over whether we should use WNT activators or WNT inhibitors to treat osteosarcoma, we hypothesize that it depends on whether the canonical or non-canonical pathways are activated, and this remains to be formally tested.”

BUFFALO, NY- September 4, 2024 – A new review was published in Oncotarget's Volume 15 on August 2, 2024, entitled, “Targeting WNT5B and WNT10B in osteosarcoma.”

As noted in the abstract of this paper, WNT signaling regulates osteosarcoma proliferation.... continue reading >>

“In medical imaging, our understanding of hepatocellular carcinoma (HCC) has long been constrained by the limitations of pixel-based analysis.”

BUFFALO, NY- August 30, 2024 – A new editorial was published in Oncotarget's Volume 15 on July 24, 2024, entitled, “Beyond pixels: Graph filtration learning unveils new dimensions in hepatocellular carcinoma imaging.”

As traditional pixel-based methods reach their limits, Graph Filtration Learning (GFL) offers a novel approach to capturing complex... continue reading >>

“We have developed a nanodrug, termed MN-anti-miR10b, that delivers anti-miR-10b antisense oligomers to cancer cells.”

BUFFALO, NY- August 28, 2024 – A new research paper was published in Oncotarget's Volume 15 on August 26, 2024, entitled, “Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties.”

As stated within the Abstract of the paper, despite advances in breast cancer screening and treatment, the prognosis for metastatic disease remains dismal, with... continue reading >>

“Properly leveraged AI-based techniques could herald a new era of precision medicine guided by non-invasive, imaging-based disease evaluation."

BUFFALO, NY- August 27, 2024 – A new editorial was published in Oncotarget's Volume 15 on August 26, 2024, entitled, “Artificial intelligence: A transformative tool in precision oncology.”

Artificial intelligence (AI) is revolutionizing society and healthcare, opening new possibilities for precision medicine. In oncology, immunotherapy (IO) has... continue reading >>

“In our study, we postulated that these differences were driven by three common low-risk (LR) missense variants: p.I157T, p.S428F, and p.T476M, all of which have a BC odds ratio of <1.4.”

BUFFALO, NY- August 26, 2024 – A new editorial was published in Oncotarget's Volume 15 on July 10, 2024, entitled, “Genotype matters: Personalized screening recommendations for germline CHEK2 variants.”

Recognized as a moderate-risk gene, CHEK2—responsible for encoding the CHK2 protein, which plays a crucial... continue reading >>

“[...] there is strong preclinical evidence that disruption of NKG2A interactions with HLA-E can stimulate both NK cell and cytotoxic T cell effector functions against cancer.”

BUFFALO, NY- August 21, 2024 – A new editorial was published in Oncotarget's Volume 15 on July 17, 2024, entitled, “Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity.”

Two studies using CRISPR screens in cancer cells identified HLA-E as a critical negative regulator of NK cell... continue reading >>

“Herein we discuss how gut microbiota and microbial metabolites regulate basal inflammation levels in the gut and the healing process of the bowel after surgery.”

BUFFALO, NY- August 19, 2024 – A new review was published in Oncotarget's Volume 15 on August 14, 2024, entitled, “The gut barrier as a gatekeeper in colorectal cancer treatment.”

Colorectal cancer (CRC) is highly prevalent and a major cause of cancer-related deaths worldwide. The primary curative treatment for CRC is surgical... continue reading >>

“In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.”

BUFFALO, NY- August 15, 2024 – A new research paper was published in Oncotarget's Volume 15 on August 14, 2024, entitled, “A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice.”

The vacuolar H+-ATPase (V-ATPase) is an ATP-dependent proton pump that functions to control the pH of... continue reading >>

“This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.”

BUFFALO, NY- August 14, 2024 – A new case report was published in Oncotarget's Volume 15 on July 17, 2024, entitled, “Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors.”

As noted in the introduction of the Abstract, the BRAF V600E substitution predicts a cancer's sensitivity to... continue reading >>

“Here we discuss the diverse forms of BRAF alterations found in human cancers and the strategies to inhibit them in patients harboring cancers of distinct origins.”

BUFFALO, NY- August 12, 2024 – A new research perspective was published in Oncotarget's Volume 15 on July 16, 2024, entitled, “Targeting the multifaceted BRAF in cancer: New directions.”

In cancer patients, BRAF-targeting precision therapeutics are effective against Class I BRAF alterations (p.V600 hotspot mutations) in tumors such ... continue reading >>

“These findings indicate that renalase-1 is a potential antigen for TCR recognition in melanoma and could be considered as a target for immunotherapy.”

BUFFALO, NY- August 8, 2024 – A new research paper was published in Oncotarget's Volume 15 on August 5, 2024, entitled, “Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival.”

As mentioned in the Abstract of this study, overexpression of the secretory protein renalase-1... continue reading >>

“Metastatic disease remains a major issue in daily practice in oncology because the outcome is still often fatal.”

BUFFALO, NY - August 7, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on July 12, 2024, entitled, “How to deal with runaway metastatic disease?”

In this new editorial, Justine Paris and Guilhem Bousquet from Université Paris Cité, Université Sorbonne Paris Nord, and APHP, Hôpital Avicenne, Oncologie médical, discussed how their research team have shown that... continue reading >>

“INT-1B3 inhibited distant tumor metastasis and significantly prolonged survival.”

BUFFALO, NY- August 5, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 12, 2024, entitled, “INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death.”

In this study, researchers Chantal L. Duurland, Thijs de Gunst, Harm C. den Boer, Marion... continue reading >>

“[...] we present the first study to retrospectively evaluate differential gene expression of MIF, DDT, and relevant pathway markers in regard to clinical outcomes in patients with melanoma.”

BUFFALO, NY- July 26, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 19, 2024, entitled, “Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.”

Macrophage Migration Inhibitory Factor (MIF) and its homolog D-dopachrome Tautomerase (DDT) have been... continue reading >>

“This study uniquely examines the prevalence and impact of the KIT M541L variant in both adult and pediatric patients with mastocytosis further stratified by disease variant.”

BUFFALO, NY- July 24, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 22, 2024, entitled, “Prevalence and impact of the KIT M541L variant in patients with mastocytosis.”

Activating mutations in KIT, particularly D816V, have been associated with mastocytosis. Additionally, expression of... continue reading >>

Oncotarget is also offering a 50% discount on publication fees until the end of the year.

BUFFALO, NY - July 22, 2024 – Oncotarget proudly welcomes new members to our esteemed Editorial Board, including our new Co-Editor-in-Chief, Dr. Wafik S. El-Deiry.

Joining Dr. El-Deiry on Oncotarget’s Editorial Board are Dr. Trever Bivona, Dr. Phillip Buckhaults, Dr. Fred Bunz, Dr. Jonathan Chernoff, Dr. Stephen G. Chun, Dr. Nathan Dolloff, Dr. Peiwen Fei, Dr. Justin D. Lathia, Dr. Bora Lim, Dr. Jia... continue reading >>

“Future development for sEphB4-HSA in HNSCC is likely to focus on patients with HPV-negative disease where there is greatest need to improve on the outcomes with pembrolizumab monotherapy.”

BUFFALO, NY- July 22, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 10, 2024, entitled, “Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.”

Patients with relapsed or metastatic head... continue reading >>

“[...] myeloid neoplasms associated with DDX41 variants likely exhibit a unique pathogenesis that diverges from the conventional understanding of myeloid neoplasms.”

BUFFALO, NY- July 19, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on July 2, 2024, entitled, “DDX41 and its unique contribution to myeloid leukemogenesis.”

In this new editorial, researcher Hirotaka Matsui, from the National Cancer Center Hospital in Tokyo, Japan, and Kumamoto University, discusses... continue reading >>

“[...] results of Tolmeijer et al. show the promise of on-treatment ctDNA detection as early read out for treatment response to potentially help guide treatment management of patients with mCRPC.”

BUFFALO, NY- July 17, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on July 2, 2024, entitled, “Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer.”

In this new editorial, researchers S.H.... continue reading >>

“[...] we found an independent positive prognostic effect of HER2-low compared to HER2-zero in early breast cancer.”

BUFFALO, NY- July 16, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity.”

In this new editorial, researchers Marcus Schmidt, Hans-Anton Lehr, and Katrin Almstedt from the University Medical Center of Johannes Gutenberg University discuss HER2 in... continue reading >>

“FDG-PET is generally considered as a useful metabolic evaluation tool, while it is also thought to have an emerging role for assessment of systemic therapy response.”

BUFFALO, NY- July 15, 2024 – A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.”

Mali... continue reading >>

“[...] it is crucial for the future application of ABC transporter inhibitors [...] to develop a stratification protocol [...] to identify those PDAC patients who are most likely to benefit from chemosensitization induced by these inhibitors.”

BUFFALO, NY- July 10, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Targeting ABC transporters in PDAC – past, present, or future?”

In this new editorial, Cecilia Bergonzini, Elisa Giovannetti and ... continue reading >>

“In this study, we investigated the therapeutic effects and the underlying mechanisms of TAS-102 in combination with regorafenib against gastrointestinal cancers.”

BUFFALO, NY- July 8, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 2, 2024, entitled, “Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status... continue reading >>

“If there was any doubt, this discovery demonstrates that genomics, extensively deployed over the past two decades, still has much to reveal to us.”

BUFFALO, NY- July 2, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Genomics has more to reveal.”

In this new editorial, researchers Laurène Fenwarth and Nicolas Duployez from the University of Lille and CHU Lille discuss molecular and cytogenetic analyses that are now used to identify... continue reading >>

“Depleting amino acid[s] likely expose[s] the Achilles heel of the cancer and exacerbate[s] DNA repair-targeted and immune-based therapy response.”

BUFFALO, NY- June 26, 2024 – A new research perspective was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Starving cancer cells to enhance DNA damage and immunotherapy response.”

Prostate cancer (PCa) poses significant challenges in treatment, particularly when it progresses to a metastatic, castrate-resistant state.... continue reading >>

“Gold nanostars amplify brain-tumor selective laser interstitial thermal therapy.”

BUFFALO, NY- June 24, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 14, 2024, entitled, “Leveraging gold nanostars for precision laser interstitial thermal therapy.”

In this new editorial, researchers Aden P. Haskell-Mendoza, Ethan S. Srinivasan, Tuan Vo-Dinh and Peter E. Fecci from Duke University discuss laser interstitial thermal therapy (LITT). Over the past decade, LITT has ... continue reading >>

“[...] these inexpensive, widely available tests with rapid turnaround times and relatively short half-lives (CEA, CA-125, and CA19-9) are perfectly situated to serve as adjunctive clinical tools in the management of NSCLC.”

BUFFALO, NY- June 19, 2024 – A new research paper was published in Oncotarget's Volume 15 on June 13, 2024, entitled, “Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management.”

Conventional tumor markers may serve... continue reading >>

“[...] immunotherapy is more likely to be effective at eliminating metastatic disease if the tumor burden is low, making it more logical to treat patients with high-risk melanomas at the earliest possible time [...]”

BUFFALO, NY- June 18, 2024 – A new research perspective was published in Oncotarget's Volume 15 on June 13, 2024, entitled, “When does a melanoma metastasize? Implications for management.”

In this new perspective, researchers John F. Thompson and Gabrielle J. Williams from The... continue reading >>

Impact Journals (Oncotarget's publisher) is sponsoring Team Open Access in the annual cycling event to end cancer: The Ride for Roswell.

BUFFALO, NY- June 11, 2024 – The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 28 years to celebrate cancer survivors, pay tribute to... continue reading >>

“The results provide novel preclinical data that demonstrate synergism between HDACi- and PARPi-mediated inhibition of DNA repair and decitabine in pancreatic cancer [...]”

BUFFALO, NY- June 5, 2024 – A new research paper was published in Oncotarget's Volume 15 on June 3, 2024, entitled, “Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy.”

Histone deacetylase inhibitors (HDACi)... continue reading >>

“[...] due to the general lack of robust predictive biomarkers, a standardized risk stratification tool is not utilized in clinical practice – a prime area for research.”

BUFFALO, NY- June 4, 2024 – A new research perspective was published in Oncotarget's Volume 15 on June 3, 2024, entitled, “Bruton’s tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.”

In this new perspective, researchers Jai N. Patel, Jai Singh, and... continue reading >>

“This consideration could be the starting point to study whether Silibinin could contrast tumor progression, aging and inflammaging through molecular and cellular mechanisms [...].”

BUFFALO, NY- May 28, 2024 – A new review paper was published in Oncotarget's Volume 15 on May 23, 2024, entitled, “The importance of integrated therapies on cancer: Silibinin, an old and new molecule.”

In this new review, researchers Elisa Roca, Giuseppe Colloca, Fiorella Lombardo, Andrea Bellieni, Alessandra ... continue reading >>

“The present studies demonstrated that GZ17-6.02 interacted with irreversible inhibitors of the EGF receptor and HER2 to kill uveal melanoma cells.”

BUFFALO, NY- May 22, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 17, 2024, entitled, “GZ17-6.02 kills PDX isolates of uveal melanoma.”

In this new study, researchers Laurence Booth, Jane L. Roberts, Ivan Spasojevic, Kaitlyn C. Baker, Andrew Poklepovic, Cameron West, John M. Kirkwood, and Paul Dent from Virginia... continue reading >>

“[...] we have characterized a pair of compounds that impact multiple processes that are relevant to cancer cell proliferation but also, and possibly more importantly, to metastasis [...].”

BUFFALO, NY- May 20, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 16, 2024, entitled, “The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response.”

The... continue reading >>

“Brazil holds the global record for penile cancer incidence.”

BUFFALO, NY- May 15, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 14, 2024, entitled, “Cyclin D1 expression in penile cancer.”

In this new study, researchers Wesliany Everton Duarte, Jaqueline Diniz Pinho, Syomara Pereira da Costa Melo, Denner Rodrigo Diniz Duarte, Juliana Martins da Guia Ribeiro do Carmo, André Salim Khayat, José Ribamar Rodrigues Calixto, Marcos Adriano Garcia Campos, Rita da Graç... continue reading >>

Oncotarget is proud to participate at the Society for Scholarly Publishing (SSP) 46th Annual Meeting, which convenes May 29–31, 2024, in Boston, Massachusetts.

BUFFALO, NY- May 13, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences, with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals.

Impact Journals is proud to participate as an exhibitor at the Society for Scholarly Publishing (SSP)... continue reading >>

“We have developed a Pix-2-Pix GAN model to perform attenuation correction on whole-body PSMA [prostate-specific membrane antigen] PET images with 18F-DCFPyL.”

BUFFALO, NY- May 8, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 7, 2024, entitled, “Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN.”

The sequential PET/CT studies oncology patients can undergo during their treatment follow-up course is limited by radiation... continue reading >>

“Our findings have implications for the natural history of prolonged or repeated SARS-CoV-2 infection as well as design of anti-COVID-19 vaccines that are administered repeatedly as booster shots.”

BUFFALO, NY- May 6, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 3, 2024, entitled, “Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer... continue reading >>

Oncotarget is a contributing sponsor at the 19th International p53 Workshop in Trieste, Italy, on May 13–16, 2024.

BUFFALO, NY- April 29, 2024 – Oncotarget is a contributing sponsor at the 19th International p53 Workshop, organized by the International Center for Genetic Engineering and Biotechnology (ICGEB), which takes place from May 13–16, 2024, in Trieste, Italy.

“Groundbreaking research and cutting-edge advancements in the field of the most studied human gene and most frequently... continue reading >>

“Our results indicate that IgM-dependent bispecific antibodies are potent therapeutic agents for B-cell malignancies.”

BUFFALO, NY- April 16, 2024 – A new research paper was published in Oncotarget's Volume 15 on April 12, 2024, entitled, “Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface.”

The B-cell receptor regulates B-cell proliferation and apoptosis. Aberrations in BCR signaling are associated with the development and... continue reading >>

“Our results reveal that MIA-602 may be a useful treatment for Doxorubicin-resistant AML [...]”

BUFFALO, NY- April 10, 2024 – A new research paper was published in Oncotarget's Volume 15 on April 8, 2024, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.”

Acute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include... continue reading >>

“[...] this trial was stopped early after 3 of the first 8 enrolled patients experienced immunotherapy-related toxicity or suspected disease progression [...]”

BUFFALO, NY- March 27, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 19, 2024, entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.”

In this new study, researchers Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong... continue reading >>

“[...] the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of (Flu+Clad+Bu) in AML cell lines and leukemia patient-derived cell samples.”

BUFFALO, NY- March 25, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.”

ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML... continue reading >>

“These results suggest strong potential for clinical use of the assay in ctDNA monitoring of solid tumor cancers.”

BUFFALO, NY- March 20, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, “Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.”

In this new study, researchers Josette Northcott, Gabor Bartha, Jason Harris, Conan Li, Fabio C.P. Navarro, Rachel Marty Pyke, Manqing Hong, Qi Zhang,... continue reading >>

“Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.”

BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center in Oncotarget's Volume 15 on March 15, 2024, entitled, “From osimertinib to preemptive combinations.”

“Here, I suggest that while first-line osimertinib extends median progression-free survival (PFS) in EGFR-mutant lung cancer compared to... continue reading >>

“[...] we present an improved method for G4 landscape determination and by applying it we show that sequence property-specific constraints of the nuclear environment mitigate G4 formation.”

BUFFALO, NY- March 18, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, “G-quadruplex landscape and its regulation revealed by a new antibody capture method.”

In this new study, researchers Subhamoy Datta, Manthan Patel, Chakkarai Sathyaseelan, Chandrama ... continue reading >>

Oncotarget is proud to participate at the American Association for Cancer Research (AACR) Annual Meeting 2024, which convenes April 5-10 in San Diego, California.

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals. 

Impact Journals will be participating as an exhibitor at the American Association for Cancer... continue reading >>

“We believe that developing GZ17-6.02 as a novel multiple myeloma agent potentially opens up a multitude of novel opportunities to develop therapeutic approaches which will prolong patient survival.”

BUFFALO, NY- March 6, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 5, 2024, entitled, “GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.”

In this new study, researchers Laurence Booth, Jane L. Roberts, Cameron West, and Paul Dent from ... continue reading >>

“[...] these results support the rationale and potential for favorable clinical outcomes of combining SG therapy with platinum-based chemotherapeutics in solid tumors.”

BUFFALO, NY- March 4, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, “Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.”

Sacituzumab govitecan (SG) is an ... continue reading >>

“Ovarian cancer (OC) is the third most prevalent type of gynecologic cancer affecting women after cervical and uterine cancer [1]. It is also considered the most fatal of all gynecological cancers [...]”

BUFFALO, NY- February 28, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, “Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health.”... continue reading >>

“The present studies were performed to extend our knowledge of GZ17-6.02 biology from that known in solid tumor cell types such as prostate cancer cells to liquid tumor cell types, for example, mycosis fungoides.”

BUFFALO, NY- February 26, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 8, 2024, entitled, “GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.”

In this new study, researchers Michael R. Booth, Laurence Booth, Jane L. Roberts,... continue reading >>

“The discovery of predictive biomarkers to paclitaxel vulnerability [such] as SSR3 [signal sequence receptor 3] promises to significantly impact cancer treatment.”

BUFFALO, NY- February 21, 2024 – A new research perspective was published in Oncotarget's Volume 15 on February 8, 2024, entitled, “Combining causal and correlative approaches to discover biomarkers of response to paclitaxel.”

As discussed in this new paper, researchers Alberto Moscona-Nissan, Karl J. Habashy, Victor A. Arrieta,... continue reading >>

“Estimates of the frequency of NTRK gene fusion in large cohorts of patients with solid tumors come from a limited number of studies. [...]. We aimed to address this gap by evaluating patients with papillary thyroid cancer (PTC) from Finland [...]”

BUFFALO, NY- February 19, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage ... continue reading >>

“Our study was designed to build specific mutational and therapeutic landscapes of pancreatic cancer among the Russian population.”

BUFFALO, NY- February 14, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis.”

About 7% of all cancer deaths are caused by pancreatic cancer (PCa). PCa is known ... continue reading >>

“[...] people of the northeastern region [of India] consume betel quid, consisting of raw areca nut [...]. People often swallow the entire betel-quid after chewing, which is believed to contribute to the development of oral, esophageal, and gastric cancers.”

BUFFALO, NY- February 12, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Differential expression of Mad2 gene is consequential to the patterns of histone H3 post-translational... continue reading >>

“[...] the results of the studies presented in this review will hopefully provide the impetus for conducting additional preclinical and clinical studies to evaluate RUX in the setting of MM as well as other types of cancer.”

BUFFALO, NY- February 7, 2024 – A new research perspective was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”

In this new paper, researchers Ashley... continue reading >>

“[...] fruitful efforts to bring more drugs from bench to bedside could only be possible if we do not leave them ‘midway’!”

BUFFALO, NY- February 5, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on January 24, 2024, entitled, “The fate of drug discovery in academia; dumping in the publication landfill?”

In this new editorial, researchers Uzma Saqib, Isaac S. Demaree, Alexander G. Obukhov, Mirza S. Baig, Amiram Ariel, and Krishnan Hajela, from Devi Ahilya... continue reading >>

“[...] this is the first study describing a BCAS1+ cell population in a large cohort of diffuse glioma patients.”

BUFFALO, NY- January 31, 2024 – A new research paper was published in Oncotarget's Volume 15 on January 24, 2024, entitled, “BCAS1 defines a heterogeneous cell population in diffuse gliomas.”

Oligodendrocyte precursor markers have become of great interest to identify new diagnostic and therapeutic targets for diffuse gliomas, since state-of-the-art studies point towards immature ... continue reading >>

“An improved understanding of the molecular basis of thyroid cancer has led to the development of new targeted agents.”

BUFFALO, NY- January 29, 2024 – A new research perspective was published in Oncotarget's Volume 15 on January 24, 2024, entitled, “Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.”

In this new paper, researchers Mark Lee and Luc GT Morris from New York Presbyterian Hospital and Memorial Sloan Kettering Cancer ... continue reading >>

“[...] this case supports a body of literature noting potentially dramatic clinical benefits of administering appropriate oncogene directed targeted therapy [...]”

BUFFALO, NY- January 24, 2024 – A new case report was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report.”

Osimertinib has been shown to be... continue reading >>

“[...] bone marrow adipocyte density, size, and roundness are significantly different between [MGUS and MM] and could provide early signs for progression [...] to MM.”

BUFFALO, NY- January 22, 2024 – A new research perspective was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.”

Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal... continue reading >>

“[...] this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.”

BUFFALO, NY- January 17, 2024 – A new research paper was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.”

Glioblastoma cells can restrict the DNA-damaging effects of temozolomide (TMZ) and radiation therapy (RT) using the... continue reading >>

“Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.”

BUFFALO, NY- January 16, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 1, 2023, entitled, “Reductive carboxylation of glutamine as a potential target in acute myeloid leukemia.”

In this new editorial, researchers Alessia Roma, Lawrence D. Goodridge and Paul A. Spagnuolo from the University of Guelph discuss acute myeloid leukemia (AML) — an aggressive cancer of... continue reading >>

“This initiative is geared towards identifying additional biomarkers that can aid in selecting the most appropriate treatments for ovarian cancer.”

BUFFALO, NY- January 10, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 22, 2023, entitled, “One more step toward treatment of PARP inhibitor-resistant ovarian cancers.”

Over 80% of ovarian cancer cases experience recurrence, resulting in roughly 12,000 annual deaths in the United States. While targeted... continue reading >>

“TAR cloning is used to genetically engineer synthetic viruses with novel properties that may be used for the development of new vaccines.”

BUFFALO, NY- January 8, 2024 – A new review paper was published in Oncotarget's Volume 14 on December 22, 2023, entitled, “Transformation-associated recombination (TAR) cloning and its applications for gene function; genome architecture and evolution; biotechnology and biomedicine.”

Transformation-associated recombination (TAR) cloning represents a unique... continue reading >>

“[...] recent significant advances in understanding [...] CSC-Exos have revealed numerous potential applications for diagnosis and treatment.”

BUFFALO, NY- January 3, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, “Therapeutically harnessing cancer stem cell-derived exosomes.”

In this editorial, researcher Yong Teng from Emory University discusses cancer stem cell-derived exosomes. Cancer stem cells (CSCs), a small population of cancer... continue reading >>